CANNABICS PHARMACEUTICALS INC. (OTCMKTS:CNBX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

0

CANNABICS PHARMACEUTICALS INC. (OTCMKTS:CNBX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION
OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.

On December 9th, 2016, Mr. Dov Weinberg resigned his position as
Chief Financial Officer of the Corporation. This decision was not
the result of any disagreement with the Company.

On the same day the Company appointed Mr. Uri Ben-Or as Chief
Financial Officer of the Corporation. Mr. Ben-Or, 46, has over 20
years of broad experience in corporate finance, accounting, MA
transactions, IPO’s and operations.

Mr. Ben-Or is CEO Founder of one of the few financial firmsin
Israel to have the International Standard on Assurance Engagement
(ISAE 3402/SAS 70 Type II) assurance with control compliances,
the new global standard for assurance reporting. He previously
served as an Auditor at PricewaterhouseCoopers Accounting Firm.

Mr. Ben-Or holds a BA degree in Business from the College of
Administration, an MBA degree from the Bar Ilan University and is
a Certified Public Accountant.

ITEM 9.01 FINANICAL STATEMENTS EXHIBITS

(d) Exhibits

99.1 Resignation of Mr. Weinberg
99.2 Board of Director Resolution naming Uri Ben-Or as CFO


About CANNABICS PHARMACEUTICALS INC. (OTCMKTS:CNBX)

Cannabics Pharmaceuticals Inc., formerly American Mining Company, is a biotechnology pharmaceutical company. The Company is engaged in pharmaceutical development. The Company is focused on development and licensing of cannabinoid-based treatments and therapies. It develops and markets various therapies and biotechnological tools aimed at providing relief from ailments that respond to active ingredients sourced from the cannabis plant. These tools include delivery systems for cannabinoids, personalized medicine therapies and procedures based on cannabis originated compounds, and bioinformatics tools. The Company’s flagship product is CANNABICS SR. CANNABICS SR is a technology for a long acting oil capsule that provides administration of cannabis. CANNABICS SR is composed solely from food grade materials and delivers effects for over 10 to 12 hours. The delivery method enables a once per day dosing regimen of medical cannabis to patients. It has not generated revenues.

CANNABICS PHARMACEUTICALS INC. (OTCMKTS:CNBX) Recent Trading Information

CANNABICS PHARMACEUTICALS INC. (OTCMKTS:CNBX) closed its last trading session down -0.010 at 0.760 with 197,476 shares trading hands.